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Danger signals activate Toll-like receptors (TLRs), thereby initiating inflammatory responses.
Canonical TLR signalling, via Toll/Interleukin-1 receptor domain (TIR)-containing adaptors
and proinflammatory transcription factors such as NF-kB, occurs in many cell types; however,
additional mechanisms are required for specificity of inflammatory responses in innate
immune cells. Here we show that SCIMP, an immune-restricted, transmembrane adaptor
protein (TRAP), promotes selective proinflammatory cytokine responses by direct modulation
of TLR4. SCIMP is a non-TIR-containing adaptor, binding directly to the TLR4-TIR domain in
response to lipopolysaccharide. In macrophages, SCIMP is constitutively associated with the
Lyn tyrosine kinase, is required for tyrosine phosphorylation of TLR4, and facilitates
TLR-inducible production of the proinflammatory cytokines IL-6 and IL-12p40. Point
mutations in SCIMP abrogating TLR4 binding also prevent SCIMP-mediated cytokine
production. SCIMP is, therefore, an immune-specific TLR adaptor that shapes host defence
and inflammation.
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C
ells of the innate immune system such as macrophages use
several families of pattern recognition receptors to detect
and respond to danger signals presented during infection,
injury and/or perturbed homeostasis1,2. The Toll-like receptors
(TLRs), single-pass transmembrane proteins at the cell surface
and in endolysosomal compartments, are the most extensively
studied of the pattern recognition receptors. Activation of
TLRs by pathogen-derived or host-derived stimuli triggers
proinflammatory signalling cascades, leading to the production
of proinflammatory mediators that are required for effective host
defence, inflammation and homeostatic repair processes. TLR4,
the archetypal member of the TLR family, cooperates with CD14
and MD2 to instigate responses to lipopolysaccharide (LPS)
from Gram-negative bacteria3. Ligand-bound, dimerized TLR4
undergoes homotypic interactions with the intracellular Toll/
interleukin-1 receptor (TIR) domains of the TIR-containing
adaptors MAL and TRAM to initiate MyD88-dependent and
TRIF-dependent TLR signalling, respectively4–6. Spatiotemporal
binding of TLR4 to different adaptors at the cell surface or in
endosomal compartments generates distinct signalling and
transcriptional programs to provide specificity to inflammatory
mediator outputs7–10. Other members of the TLR family also
couple with TIR-containing adaptors at the cell surface or in
endosomes to generate specificity in signalling responses. The
nature of the specific cytokines produced on TLR activation is
critical for mounting a robust and effective immune defence, and
for the subsequent resolution of inflammation and restoration of
homeostasis. However, TIR-containing adaptor proteins are
widely expressed, and additional mechanisms or adaptors that
enable either heightened or more selective inflammatory
responses in innate immune cells are not well understood.
Members of the transmembrane adaptor protein (TRAP)
family scaffold signalling proteins and kinases to support
receptor-mediated signalling in other immune cells11. For
instance, linker of activation for T cells (LAT) directly and
indirectly recruits and activates signalling molecules, including
Grb2, PLCg1, SLP-76 and Vav1, downstream of activated T-cell
receptors12. Consequently, LAT is essential for T cell
development13,14, and for mature T cell functions15. LAT is a
member of the palmitoylated TRAP (pTRAP) subfamily, which is
notable for its signature palmitoylation-directed targeting to
specific membrane microdomains11. Current evidence for pTRAP
regulation of innate immune receptors is limited, resting on a
small number of studies relating to TREM signalling in
macrophages16,17. To date, specific roles for TRAPs in direct
TLR signalling have not been investigated.
The most recently described member of the pTRAP family is
SLP adaptor and C-terminal Src kinase (CSK)-interacting
membrane protein (SCIMP), which has been reported to associate
with Src family kinases (SFKs) and to regulate MHC class II
signalling in B cells18 and Dectin-1 signalling in dendritic cells19.
Recent evidence also posits SCIMP as a potential disease-related
gene in human autoimmune and neurodegenerative conditions20,21.
In this study, we examine possible roles for pTRAPs in TLR-driven
innate immune responses. We find that SCIMP acts as
an unconventional, non-TIR-containing TLR adaptor in
macrophages, directly binding to TLR4 and orchestrating its
ligand-induced tyrosine phosphorylation. Moreover, we show that
SCIMP is a TLR signalling adaptor that provides remarkable
selectivity to proinflammatory cytokine responses downstream of
multiple TLRs. SCIMP is thus an important regulator of host innate
immune responses to danger signals.
Results
SCIMP is a transmembrane adaptor for TLR4 in macrophages.
Examination of pTRAP family member expression across
immune and non-immune cell populations highlighted the
marked expression of SCIMP in primary mouse bone marrow-
derived macrophages (BMM), as well as in the RAW264.7 and
WR19M macrophage-like cell lines, whereas it was not detectable
in the non-myeloid cells that were screened (Fig. 1a). No other
pTRAP displays this selective expression pattern (Supplementary
Fig. 1a), and we were drawn to further investigate possible SCIMP
functions in macrophages. The cellular localization of SCIMP was
examined by immunostaining in primary macrophages (BMM;
Supplementary Fig. 1b) and in RAW264.7 cells (Fig. 1b). In both
cases, SCIMP staining was apparent on intracellular punctate
membranes, but was particularly prominent on the macrophage
plasma membrane, where it was further concentrated in cell
surface projections, notably the filopodia and ruffles of some cells.
This localization was replicated by expression of green fluorescent
protein (GFP)-SCIMP (Fig. 1c), and at an ultrastructural,
cryo-EM level, immunogold labelling of GFP clearly depicts
GFP-SCIMP labelling on the plasma membrane at sites of
protrusions and ruffles (Fig. 1d). Quantification of the gold
labelling shows SCIMP to be enriched B4 fold in ruffles
compared with other stretches of plasma membrane (Fig. 1d).
Both the dorsal ruffles and filopodia of macrophages are
cholesterol-rich membranes replete with lipid raft microdomains,
and these sites are also enriched with immune receptors,
including some TLRs10,22,23. Thus SCIMP at these sites is
positioned to participate in pathogen detection and/or receptor-
mediated activation of macrophages.
To determine whether this adaptor is associated with specific
receptor pathways, we performed unbiased screens to identify
possible SCIMP binding partners in activated macrophages.
GST-SCIMP was used for pull-down assays, along with a protease
cleavage and elution strategy24, to optimize capture of genuine
binding partners from lysates of activated macrophages.
LC/MS/MS analysis of SCIMP-bound proteins in LPS-activated
macrophages identified the SFK Lyn and the adaptor protein
Grb2 (Fig. 1e), which were previously identified as SCIMP
partners in B cells18. In addition, one of the top hits identified
from this analysis was TLR4 (Fig. 1e,f and Supplementary
Fig. 1c), the prototypical TLR and a previously unidentified
binding partner of SCIMP. To verify this association in cells, we
performed immunoprecipitation (with a V5 antibody) from
macrophages expressing V5-tagged SCIMP. Consistent with
the LC/MS/MS data (Fig. 1f), immunoblotting confirmed the
co-immunoprecipitation of Lyn and Grb2, which were
constitutively bound to SCIMP (Fig. 2a). In addition, TLR4
co-immunoprecipitated with SCIMP, and in this case, the
interaction was strictly LPS-induced (Fig. 2a), occurring
rapidly after ligand activation. A phospho-specific antibody
recognizing active SFKs (pY416 Src) reveals that LPS acutely
and transiently activates an SFK in this complex (Fig. 2a),
which is consistent with, and likely to be, Lyn. Thus, we reveal
SCIMP as a component of LPS-activated TLR4 complexes in
macrophages.
pTRAPs are typically associated with cholesterol-rich
membrane microdomains and detergent-resistant fractions.
For instance, SCIMP is enriched in tetraspanin-enriched
microdomains in B cells18. Here we show that in LPS-treated
macrophages, SCIMP and Lyn are also enriched in detergent-
resistant membrane fractions, as marked by flotillin
(Supplementary Fig. 1d). This is consistent with the nature of
pTRAPs and with the localization of SCIMP in cholesterol-rich
filopodia and ruffles (Fig. 1b–d). This is also significant for the
association of SCIMP with TLR4, which is also in lipid raft
domains and detergent-resistant fractions6. However, the
apparent interaction between SCIMP and TLR4 in activated
macrophages (Fig. 2a) was not merely a consequence of SCIMP
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being partitioned into LPS-induced microdomains, since there
was no non-specific pull-down of the lipid raft marker flotillin in
immunoprecipitates (Supplementary Fig. 1e). Finally, we sought
verification that SCIMP and TLR4 colocalize in cells by
co-expressing HA-tagged TLR4 and V5-SCIMP in activated
macrophages. We have previously shown that TLR4 is
concentrated in dorsal ruffles, which act as sites for initiation of
signalling in LPS-activated macrophages23. Here the joint
labelling depicts a concentration of HA-TLR4 in these
actin-rich ruffle membranes where it colocalizes with
V5-SCIMP (Fig. 2b). Together these results indicate that
SCIMP and LPS-activated TLR4 are co-located in plasma
membrane domains that are also signalling-competent locales.
SCIMP exerts selective effects on macrophage TLR responses.
Given the contributions of other pTRAPs to immune receptor
signalling in T and B cells, we next examined a role for SCIMP as
a signalling adaptor in its guise as a direct, LPS-induced binding
partner of TLR4. The LPS-mediated phosphorylation of ERK,
p38 and JNK MAPKs is impaired after small interfering RNA
(siRNA) silencing of SCIMP in primary macrophages (BMM).
SCIMP-silenced cells also have a modest but significant
impairment in LPS-triggered degradation of IkB (Fig. 3a,b).
Interestingly, this effect on signalling responses is very transient;
for example, SCIMP silencing impairs p38 MAPK activation at
30 min, but not at 60 min, post-LPS, and by 120 min most of the
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Figure 1 | Immune-restricted SCIMP is a TLR4-associated cell surface protein enriched in microdomains. (a) mRNA expression of SCIMP was assessed
in the indicated fibroblast, lymphoid and myeloid cell lines. Data represents meanþ s.e.m. (n¼ 3). (b) Immunostaining of endogenous SCIMP in
LPS-activated RAW264.7 cells (green) on filopodia; cells were co-stained with phalloidin (red) and 40,6-Diamidino-20-phenylindole dihydrochloride (DAPI;
blue). (c) Fluorescent imaging of LPS-treated (30 min) RAW264.7 cells transiently transfected with SCIMP-GFP (green). The cells were co-stained with
DAPI (blue). (d) Immunogold labelling on cryo-EM sections of RAW264.7 cells stably expressing GFP-SCIMP. GFP labelling ruffles at the cell surface.
N¼ nucleus. Gold particles on ruffle or filopodia membranes versus other stretches of plasma membrane were counted (n¼ 5 cells). Significance was
assessed using the Student’s t-test (**Po0.01). (e) GST-SCIMP-T1 coupled to GSH-Sepharose was used for pull-downs from LPS-activated RAW264.7 cell
extracts. Bound proteins were eluted by a protease cleavage elution method and separated by SDS–PAGE. Excised bands were identified by liquid
chromatography and mass spectrometry (LC/MS/MS). A band at B100 kDa, absent from the GST control, was identified as TLR4. (f) List of the top hits
from the LC/MS/MS analysis of SCIMP-GST pull downs. Data in a–f are representative of at least three independent experiments. Scale bars in b–d
represent 10mm, 20mm and 10 nm, respectively.
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Supplementary Fig. 2a). The transient effect of SCIMP on TLR
signalling responses was not explored further, but these findings
suggest that SCIMP is likely to have partial or selective effects on
downstream biological responses. To test this, we examined
LPS-induced cytokine outputs in SCIMP-silenced BMM. Indeed,
after depletion of SCIMP with two specific siRNAs, the synthesis
and secretion of the proinflammatory cytokines interleukin 6
(IL-6) and IL-12p40 are substantially reduced, while remarkably,
tumor necrosis factor (TNF) is unaffected (Fig. 3c,d). These
effects are discriminating for TLR signalling, as TNF-inducible
IL-6 and IL-12p40 production were unaffected by SCIMP
silencing in BMM (Fig. 3e). Further verifying this response,
we find that retroviral transduction and overexpression of SCIMP
in BMM selectively amplifies LPS-inducible production of
IL-12p40, but not of TNF (Supplementary Fig. 2b). Examination
of additional cytokines further attests to this selectivity, since
levels of the TLR-inducible cytokines IFN-b, IL-10 and IL-12p70
are all unaffected by SCIMP silencing in BMM (Supplementary
Fig. 2c). SCIMP additionally does not regulate inducible
expression of specific MyD88-dependent (for example, Il1b and
Ccl7) or MyD88-independent (for example, Ifnb and Cxcl10)
TLR4 target genes (Supplementary Fig. 2d).
Having examined the effects of SCIMP depletion on
TLR4-triggered cytokine outputs, we next extended our analysis
to examine possible roles downstream of other TLRs. siRNA
silencing of SCIMP in BMM reduced the inducible production of
IL-6 and IL-12p40, but not TNF, in response to agonists of TLR3
(Poly(I:C)), TLR7 (imiquimod) and TLR1/2 (Pam3CSK4)
(Supplementary Fig. 3a–c). As an alternative and complementary
approach, we also assessed the effect of CRISPR/Cas9-mediated
SCIMP deletion on TLR responses in RAW264.7 cells. As
expected, deletion of SCIMP in multiple clonal cell lines
(Supplementary Fig. 4a) did not impair either LPS-inducible
TNF production (Supplementary Fig. 4b) or LPS-/Pam3CSK4-
induced TNF secretion (Supplementary Fig. 4c,d). However,
the secretion of IL-6 at the behest of LPS-activated TLR4
or Pam3CSK4-activated TLR1/2 was significantly reduced
(Supplementary Fig. 4c,d). The low levels of LPS-inducible
IL-12p40 secretion were also reduced, whilst Pam3CSK4-
inducible IL-12p40 secretion from RAW264.7 cells could not be
detected. Thus, CRISPR/Cas9-mediated SCIMP deletion
corroborated the results obtained with siRNA depletion of
SCIMP in BMM. Taken together, these findings show that, in
the context of an otherwise broad cytokine programme induced
by TLRs, the adaptor SCIMP is responsible for driving a uniquely
selective subset of key proinflammatory cytokines, namely IL-6
and IL-12p40. To uncover the mechanism for this selective
cytokine regulation, we next dissected the interaction between
SCIMP and TLR4 in more detail.
Phosphorylation of SCIMP at Y96 enhances binding to TLR4.
The canonical model for adaptor interactions with TLRs is via
direct, homotypic interactions between the TIR domains of TLRs
and TIR domain-containing adaptor proteins (MAL, MyD88,
TRIF, TRAM and SARM)4–6. Despite SCIMP lacking a TIR
domain, our pull-down experiments suggested at least a close
association between SCIMP and TLR4. Like other TRAPs, SCIMP
has a short extracellular domain and a long cytoplasmic tail. The
intracellular domain contains a proline-rich domain (PRD) and
several tyrosine residues that can be phosphorylated by Lyn
(refs 11,18). Two truncated forms of the SCIMP cytoplasmic tail
were produced (Fig. 4a), T1 (entire intracellular region: amino
acids 29–150) and T2 (C terminal region: amino acids 93–150).
The cytoplasmic TIR domain (amino acids 670–835) of TLR4 was
also produced, and in in vitro pull-downs using recombinant
proteins, we find that both GST-SCIMP-T1 and T2 bind to the
His-TLR4-TIR domain (Fig. 4b). Thus, the C-terminal TLR4-TIR
domain and the C-terminal region of SCIMP (amino acids
93–150) can directly interact. To confirm this binding in cell
lysates, GST-SCIMP T1 and T2 were used for pull-downs from
LPS-activated macrophage extracts. SCIMP-T1, and to a lesser
extent SCIMP-T2, pulled down endogenous TLR4 (Fig. 4c).
Importantly, neither GST-SCIMP T1 nor T2 interacted with
endogenous TLR4 in extracts of unstimulated macrophages,
whereas GST-SCIMP T1 pull-downs show constitutive binding of
Lyn (Supplementary Fig. 5a). These data confirm that, whereas
SCIMP interacts constitutively with Lyn in macrophages, its
interaction with TLR4 is agonist-induced. Moreover, the
pull-down experiments (Fig. 4c) confirm binding of TLR4 to
the C-terminus of SCIMP, but also suggest that other regions of
SCIMP, in addition to S93-F150, contribute to the stronger
binding offered by the longer T1 construct under in-cell
conditions. Hence, analysis of the interaction between
recombinant SCIMP-T1 and recombinant TLR4-TIR (Fig. 4b)
is unlikely to capture all of the factors involved in the interactions
between these proteins within macrophages. As expected,
SCIMP-T2, which lacks the PRD, does not interact with Lyn
(Fig. 4c and Supplementary Fig. 5a). Finally, the in vitro
interaction between SCIMP and TLR4 was analysed in
fluorescence binding assays using recombinant, fluorescently
Anti-TLR4
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Figure 2 | SCIMP is recruited to TLR4 in macrophages on LPS activation.
(a) V5-labelled SCIMP was stably expressed in RAW264.7 macrophages,
cells were treated with LPS, and at the indicated times, the V5 antibody was
used for immunoprecipitation. Samples were probed for TLR4, pSFK(Y416),
Lyn, Grb2 and V5-SCIMP. (b) Confocal imaging of LPS-treated (30 min)
RAW264.7 cells transiently co-expressing TLR4-HA (green) and SCIMP-V5
(red), with phalloidin (blue). TLR4 and SCIMP are colocalized (white) on
dorsal surface ruffles, as shown for separate channels in the Z projections.
Data in a and b are representative of three independent experiments.
The scale bar in b represents 10mm.
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Figure 3 | SCIMP is required for a subset of proinflammatory cytokine responses in macrophages. (a) SCIMP was silenced by siRNA in BMM.
Representative immunoblots showing levels of SCIMP, IkB, phospho-JNK, phospho-p38 and phospho-ERK1/2 at 0, 30 and 60 min post-LPS stimulation.
(b) Relative chemiluminescence of IkB, phospho-JNK, phospho-ERK1/2 and phospho-p38 was assessed at 30 min and 60 min post-LPS stimulation in
SCIMP-silenced BMM. Graphs represent pooled data from n¼ 3 experiments (meanþ s.e.m.). (c,d) SCIMP silencing in BMM reduces proinflammatory
cytokine production at the mRNA (c) and protein (d) level. Levels of individual mRNAs, relative to Hprt, at 4 h post-LPS stimulation were assessed by qPCR
(n¼4 experiments), and levels of secreted cytokines at 24 h post-LPS stimulation were assessed by enzyme-linked immunosorbent assay (ELISA; n¼4
experiments). Graphs depict meanþ s.e.m. (e) IL-6 and IL-12p40 protein levels were assessed by ELISA in SCIMP-silenced BMM treated with LPS or
TNF for 24 h. Data is representative of two independent experiments. Graphs depict meanþ range from technical repeats (n¼ 2). Data in (a–d) are
representative of, or combined from, at least 3 independent experiments. For (b–d), significance was assessed using one-way ANOVA (*Po0.05 and
**Po0.01; NS, not significant).
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labelled SCIMP-T1 and TLR4-TIR (Fig. 4d, left panel); these
experiments show that the direct in vitro interaction occurs with
moderately high affinity (212 nM; Fig. 4d, right panel). Based
on these findings, we reveal novel binding, through an
unconventional mode, between a non-TIR adaptor and the TIR
domain of TLR4.
As the SCIMP-TLR4 interaction is not only direct (Fig. 4b,d),
but also ligand-dependent (Fig. 2a), we next examined whether
tyrosine phosphorylation of SCIMP regulates binding. Three
tyrosines in the cytoplasmic domain are conserved between
human and mouse SCIMP (Fig. 4a). Phosphorylation-deficient
mutagenesis of each of these residues reveals that only the Y96F
mutation attenuates binding of GST-SCIMP-T1 to endogenous
TLR4 in extracts from LPS-activated macrophages (Fig. 5a). By
contrast, phosphorylation of these tyrosines is not required for
binding to Lyn, which binds to the PRD of SCIMP18. Mutation
of a residue (W95) adjacent to Y96 in GST-SCIMP-T1 also
substantially reduces binding to recombinant His-TLR4-TIR
(Fig. 5b), further highlighting the importance of this region of
SCIMP for its interaction with TLR4. In contrast, testing
the capacity of GST-SCIMP mutants to bind recombinant
His-TLR4-TIR (rather than TLR4 from LPS-activated
macrophages) shows the (unphosphorylated) Y96F SCIMP
mutant still binds TLR4 (Fig. 5b), thus indicating that
phosphorylation is not required for in vitro binding. These data
therefore suggest that extracts from LPS-activated macrophages
trigger phosphorylation of GST-SCIMP at Y96, enhancing its
binding to endogenous TLR4. Hence, the affinity of the
interaction between phosphorylated SCIMP and TLR4 in
LPS-activated cells is likely to be much greater than that
observed when using recombinant proteins (Fig. 4d).
To directly address this, we performed in vitro binding assays,
using recombinant TLR4-TIR domain and short SCIMP-
derived peptides (amino acids 90–107) containing either
unphosphorylated or phosphorylated Y96. These experiments
show that the SCIMP-derived peptide-containing phosphorylated
Y96 binds to TLR4 with much greater affinity than the
unphosphorylated peptide (Fig. 5c,d). Finally, the requirement
for SCIMP Y96 phosphorylation for in vivo binding to TLR4 was
tested in cells stably expressing full-length proteins. As previously
observed (Fig. 2a), LPS triggers an association between SCIMP
and TLR4, however this does not occur with the SCIMP-Y96F
mutant (Fig. 5e). Collectively, the above data define SCIMP as a
new direct binding partner and non-TIR adaptor for TLR4, and
delineate a new recruitment mechanism, in which tyrosine
phosphorylation of SCIMP, most likely by Lyn, enables it to
directly bind to the TLR4 TIR domain. The consequences of
SCIMP binding to TLR4, and the direct involvement of Lyn in
these processes, were next examined.
SCIMP is required for tyrosine phosphorylation of TLR4.
The interaction of SCIMP with TLR4 likely underpins SCIMP-
mediated regulation of cytokine production, but several possible
mechanisms could account for this effect. For instance,
LPS induces the endocytosis of surface-activated TLR4, which
is critical for eliciting specific cytokine outputs generated by
endosomal signalling events that are distinct from those at the cell
surface25,26. To gauge whether SCIMP alters TLR4 endocytosis,
the surface expression and ligand-dependent internalization of
TLR4 were measured in BMM after siRNA silencing of SCIMP.
In these experiments, both basal TLR4 expression and
endocytosis of TLR4 were unaffected (Supplementary Fig. 5b,c).
We next investigated whether there may be interplay between
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Figure 4 | SCIMP interacts directly with TLR4. (a) A schematic diagram depicting T1, T2 or full-length (FL) murine SCIMP with transmembrane
domain (TMD), PRD, tyrosine residues 58, 96 and 120 (green bars) and N- and C-terminal amino acids. (b) Bacterially expressed GST tag alone,
or GST-tagged SCIMP T1 or T2 was used to pull-down recombinant His-TLR4-TIR. (c) GST-SCIMP T1 or T2 fusion proteins were used in GST pull downs
with extracts from LPS-activated RAW264.7 cells and probed for TLR4 and Lyn. (d) Titration of fluorescently labelled SCIMP-T1 with TLR4-TIR (left panel),
with Kd (212 nM) determined by curve fit analysis (right panel). Data in b and c are representative of three independent experiments.
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SCIMP and TIR-containing adaptors. Here we find that, although
SCIMP interacts with TLR4 on LPS activation, it does not interact
with the proximal TLR4 adaptor MAL, under the same
conditions (Supplementary Fig. 5d). Furthermore, SCIMP is
still recruited to TLR4 in the absence of MyD88 (Supplementary
Fig. 5e). These findings further highlight the distinct nature of the
SCIMP-TLR4 interaction, and suggest that other mechanisms
likely account for SCIMP-dependent, TLR4-inducible cytokine
production.
TLR4 (ref. 27), as well as several other TLRs including
TLR2 (refs 28–30), TLR3 (ref. 31) and TLR8 (ref. 32),
are tyrosine phosphorylated in a ligand-dependent manner.
Given that SCIMP is required for responses to multiple TLRs
(Supplementary Figs 3a–c and 4c,d) and since other TRAPs act as
adaptors linking SFKs to receptors for phosphorylation11,
we considered the possibility that SCIMP may be recruited to
facilitate the ligand-dependent phosphorylation of TLR4. Indeed,
we find that LPS-induced tyrosine phosphorylation of TLR4 is
dramatically reduced on siRNA silencing of SCIMP in primary
macrophages (Fig. 6a). The opposite effect is apparent when
SCIMP is overexpressed in RAW264.7 cells, with markedly
increased levels of LPS-induced phospho-TLR4 being observed
(Fig. 6b). Thus, the direct interaction of SCIMP with TLR4
facilitates tyrosine phosphorylation of TLR4 in response to LPS,
offering a possible mechanism for delineating selective cytokine
outputs. To determine whether the SCIMP-TLR4 interaction is
indeed required for LPS-inducible, SCIMP-dependent cytokine
production, we examined the functional capacity of the SCIMP
Y96F and W95A mutants, which do not interact with TLR4 in
cells or in vitro, respectively (Fig. 5a,b,e). As predicted, these
mutants are unable to amplify LPS-inducible production of the
SCIMP-dependent cytokine IL-12p40 when overexpressed
in primary macrophages (BMM), whereas wild-type SCIMP
selectively promotes LPS-inducible IL-12p40 but not TNF
production (Fig. 6c). Interestingly, there was a modest but
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Figure 5 | Phosphorylation of SCIMP at Y96 enhances binding to TLR4. (a) Pull-down assays using LPS-activated RAW264.7 cell lysates and
GST-tagged tyrosine to phenylalanine (Y to F) mutants of SCIMP-T1. SCIMP interactions with either TLR4 or Lyn were assessed by immunoblotting.
(b) GST pull-down assays were performed using GST-SCIMP mutants and recombinant His-tagged TLR4-TIR domain, and binding was evaluated using
immunoblotting against His-TLR4-TIR (upper panel). Quantification of immunoblots was performed using densitometry. Data are combined from two
independent experiments (meanþ range, lower panel). (c) Phosphorylation at Y96 enables SCIMP to bind to TLR4. Titration of fluorescently labelled
p-Y96-containing (red) or Y96-containing (green) SCIMP-derived peptides (aa 90–107) with TLR4-TIR. Inset shows fluorescence recovery over a longer
time course with unlabelled p-Y96 peptide. (d) The Kd (159 nM and42.5mM for p-Y96- and Y96-containing peptides, respectively) was determined by
curve fit analysis. (e) SCIMP phosphorylation at Y96 is required for in vivo TLR4 binding. RAW264.7 cells stably expressing wild type (WT) or Y96F SCIMP
were used to assess the agonist-induced SCIMP-TLR4 interaction, by co-immunoprecipitation of SCIMP followed by immunoblotting for TLR4 and
SCIMP (left). The level of TLR4 pull-down was quantified relative to SCIMP levels (right) to correct for minor differences in levels of WT versus Y96F
SCIMP expression (meanþ s.e.m.). Data in a are representative of three independent experiments, data in b are representative of (top) or combined from
(bottom) n¼ 2 independent experiments, and data in e are representative of three independent experiments (left) or combined from n¼ 3 independent
experiments (right).
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Figure 6 | SCIMP drives cytokine selectivity by scaffolding the SFK Lyn for TLR4 phosphorylation. (a) siRNA-mediated SCIMP knockdown in BMM
reduces tyrosine phosphorylation of TLR4. After SCIMP silencing (lysates, bottom panels), cells were stimulated for 30 min with LPS, TLR4 was
immunoprecipitated and blots were probed for anti-phospho-tyrosine. (b) SCIMP overexpression increases tyrosine phosphorylation of TLR4. RAW264.7
cells stably transfected with empty vector or SCIMP were treated with 30 min with LPS, after which TLR4 was immunoprecipitated and tyrosine
phosphorylation was assessed by immunoblotting. (c) IL-12p40 and TNF cytokine production was assessed in primary macrophages (BMM), retrovirally
transduced with empty vector (EV), wild-type SCIMP (WT), Y96F SCIMP or W95A SCIMP, at 24 h post-LPS stimulation (meanþ s.e.m.). SCIMP protein
expression in transduced BMM is shown in the panel on the right. (d) The Src kinase inhibitor SU6656 impairs SCIMP tyrosine phosphorylation and its
interaction with TLR4, as assessed by SCIMP immunoprecipitation experiments from lysates of RAW264.7 cells stimulated with LPS for 5 min. (e) Lyn is
essential for LPS-induced SCIMP phosphorylation, as well as the interaction between SCIMP and TLR4 as assessed by SCIMP immunoprecipitation from
lysates of WT and Lyn / BMM stimulated with LPS for 5 min. (f) BMM were pre-treated with SU6656 for 30 min and then stimulated with LPS for 4 h or
8 h. Secreted cytokines (IL-12p40, IL-6 and TNF) were measured by enzyme-linked immunosorbent assay (ELISA; meanþ s.e.m.). (g) The effect of SU6656
on cell death in LPS-activated BMM was assessed using the LDH release assay. LDH in culture supernatants was measured as a percentage of total cellular
LDH at 8 h post-LPS stimulation from the same samples as in f (meanþ s.e.m.). (h) Levels of LPS-induced cytokines (IL-6, IL-12p40 and TNF; ELISA) in
culture supernatants from wild type (WT) and Lyn / (KO) BMM were assessed at 24 h post-stimulation (meanþ s.e.m.). All experiments were repeated
at least 3 times, and all graphical data are pooled from at least n¼ 3 independent experiments (meanþ s.e.m.). Significance was assessed using one-way
ANOVA in c, f and h (*Po0.05 and **Po0.01).
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production for the Y96F mutant versus empty vector. This could
relate to the fact that, although this mutant is unable to be
phosphorylated, it can still bind to Lyn (Fig. 5a) and thus may
have a dominant-negative effect on this signalling response.
Lyn phosphorylates SCIMP to enable an interaction with TLR4.
In B cells, MHC-II cross-linking triggers SCIMP phosphorylation18.
In macrophages treated with either LPS or Pam3CSK4, SCIMP was
rapidly phosphorylated (Supplementary Fig. 5f), consistent with the
requirement for this pTRAP in cytokine responses downstream of
multiple TLRs (Supplementary Figs 3a–c and 4c,d). Although
SCIMP is constitutively associated with Lyn in macrophages
(Fig. 2a), the role of this SFK in TLR signalling is complex, and
somewhat controversial. It has been reported to both inhibit and
enhance TLR responses in different cell types and in different in vivo
settings33–36. We therefore more directly assessed the involvement of
Lyn in the TLR4-SCIMP pathway. In support of a model in which
activated Lyn phosphorylates SCIMP to enable an interaction with
TLR4, we found that a SFK inhibitor impairs LPS-induced
phosphorylation of endogenous SCIMP, as well as the interaction
between SCIMP and TLR4 (Fig. 6d). Moreover, both SCIMP
phosphorylation and its inducible association with TLR4 were
ablated in BMM from Lyn / mice (Fig. 6e). Thus, both
pharmacological and genetic approaches posit Lyn as an essential
upstream kinase for the agonist-induced association between SCIMP
and TLRs. A further prediction of this model is that, if SCIMP is
unable to bind to TLR4 for its tyrosine phosphorylation, TLR4
signalling for production of SCIMP-dependent cytokines will be
impaired. Accordingly, a SFK inhibitor selectively reduces IL-6 and
IL-12p40, but not TNF, production from BMM (Fig. 6f), without
affecting cell viability (Fig. 6g). Similarly, Lyn / BMM were
compromised for LPS-inducible IL-6 and IL-12p40 production
(Fig. 6h). In this case, TNF production was also somewhat reduced,
which likely reflects a broader role for Lyn beyond its function in
the SCIMP pathway. We thus conclude that Lyn-mediated
phosphorylation of immune-restricted SCIMP at Y96 enables an
unconventional interaction with the TIR domain of LPS-activated
TLR4. SCIMP-mediated phosphorylation of TLR4 then serves as a
mechanism to initiate a transient proinflammatory signalling code
that selectively produces the inflammatory mediators IL-6 and
IL-12p40 in the context of acute inflammatory responses. Given that
several TLRs are tyrosine phosphorylated27,28,31,32, and that SCIMP
directs similar cytokine outputs from multiple TLRs (Supplementary
Figs 3a–c and 4c,d), this pTRAP is likely to control other TLR
responses through a shared mechanism. Overall, SCIMP is thus
revealed as a key, agonist-inducible signalling adaptor and scaffold
for phosphorylation of TLRs to enable specific proinflammatory
cytokine responses.
Discussion
In this study, we extend the known range of pTRAP adaptor
functions to the control of signalling from the TLR family. The
immune-restricted expression of the pTRAP family member
SCIMP, particularly in macrophages, and its enrichment in
signalling-rich membrane domains, position this adaptor as a
controller of TLR-mediated innate immune signalling responses.
We identified a unique proinflammatory cytokine signature for
SCIMP, which was operational through multiple TLRs. To
delineate the nature of SCIMP binding and the mechanism for
its role in signalling and cytokine regulation, in-depth studies
were carried out on LPS-activated TLR4. The findings reveal that
LPS triggers rapid Lyn kinase activation, leading to Lyn-mediated
phosphorylation of SCIMP at Y96 and the inducible interaction
between TLR4 and SCIMP via unconventional TIR-non-TIR
domain binding (see model in Supplementary Fig. 6). The
association between TLR4 and SCIMP enables tyrosine phos-
phorylation of TLR4 (most likely via SCIMP-associated Lyn),
thus initiating a transient TLR4 signalling response, particularly
in the MAPK signalling arms. This SCIMP-mediated pathway
results in the synthesis and secretion of primarily the key
proinflammatory cytokines IL-6 and IL-12p40. This fine-tuning
of inflammatory signalling pathways represents a remarkable
level of selectivity within the broader TLR-dependent cytokine
profile elicited by innate immune cells.
Since the mid-1990s, the TLR signalling field has focused
almost exclusively on the role of the MyD88, MAL, TRAM and
TRIF TIR-containing adaptors in providing signal bifurcation.
MyD88, alone or in combination with MAL, drives a MyD88-
dependent gene expression programme37,38. Similarly, TRIF,
alone or in combination with TRAM, promotes the so-called
MyD88-independent gene expression programme, typified by
interferon regulatory factor 3-mediated induction of IFN-b
expression39,40. Recent studies on the TIR-containing BCAP
adaptor, which links TLRs to PI3K/Akt activation and negative
regulation of cytokine outputs41,42, have highlighted additional
layers of complexity that exist in adaptor-mediated control
of TLR responses. Now, our identification of SCIMP as a
non-TIR-containing adaptor mediating TLR4 phosphorylation
provides a completely new class of TLR adaptor and a new mode
of TLR adaptor recruitment for subsequent signalling responses.
Importantly, it also defines a new axis for signal bifurcation.
SCIMP is an early hierarchical recruit to LPS-bound TLR4,
mediating receptor phosphorylation, a transient signalling
response and a selective effect on downstream inflammatory
outputs. The interplay between SCIMP and TIR-containing
adaptors during acute TLR signalling responses is an area of
ongoing investigation, however we find that MyD88 is not
required for the LPS-inducible association between TLR4
and SCIMP (Supplementary Fig. 5e). This finding is consistent
with a recent study, which found no role for MyD88 in
SCIMP responses downstream of zymosan19. The concentration
of SCIMP in cell surface ruffles and projections and its
fractionation in detergent-resistant membrane fractions
(Fig. 1b,d and Supplementary Fig. 1b,d) are both consistent
with the known enrichment of pTRAP family members in lipid
raft domains and with the enrichment of TLR4 in membrane
ruffles and lipid rafts6,11,23. Moreover, SCIMP is also on
intracellular membranes (Supplementary Fig. 1b), and its
activation (Supplementary Fig. 5f) and requirement for cytokine
production downstream of multiple TLRs (Supplementary
Figs 3a–c and 4c,d) suggests that it is likely to function from
both endosomal environments (for example, TLR3 and TLR7)
and from the cell surface (for example, TLR1/2).
Despite the central role of tyrosine phosphorylation of
receptors in signal transduction pathways, only a limited number
of studies have investigated this in the context of TLRs. TLR2
(refs 29,30), TLR3 (ref. 43) and TLR4 (refs 27,44,45) are all
known to be tyrosine phosphorylated in an agonist-induced
manner. In the case of TLR4, Lyn kinase has been chiefly
implicated as the responsible kinase27, although Syk is also
reported to phosphorylate TLRs (ref. 46). Our findings here
identify SCIMP as an essential mediator of LPS-induced TLR4
tyrosine phosphorylation (Fig. 6a,b), and Lyn as being a positive
regulator of TLR4 signalling (Fig. 6f,h) that is indispensible for
the SCIMP-TLR4 interaction (Fig. 6d,e). Our data thus supports
a model in which Lyn is required for TLR4 tyrosine
phosphorylation in macrophages, although it is likely that other
tyrosine kinases may contribute to and diversify patterns of TLR4
phosphorylation, for example, to provide cell-type-selectivity to
such responses. Our discovery of the SCIMP-Lyn-TLR4 axis may
also help explain some of the apparently contrasting roles for
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Lyn in TLR signalling responses. For example, Lyn has been
reported to inhibit TLR-mediated inflammatory responses in
macrophages34, but promote similar responses in dendritic
cells35,36. Under our experimental conditions, Lyn promotes
LPS-inducible IL-12p40 and IL-6 production in macrophages
(Fig. 6f,h), which is also consistent with our functional data on
SCIMP (Fig. 3c–e). Given that SCIMP constitutively associates
with Lyn in macrophages (Fig. 2a), its presence or absence in a
particular cellular context is likely to be a critical determinant of
how Lyn participates in TLR responses.
Despite knowledge of specific tyrosine kinases that mediate
TLR phosphorylation, how this process is actually initiated was
previously unknown. Our studies on SCIMP have solved this
puzzle by unravelling this pTRAP member as an essential adaptor
directly linking Lyn to TLR4 in macrophages. Previous studies
have shown that Y674 within human TLR4 (mouse equivalent:
Y672) is necessary for TLR4 dimerization and TIR-mediated
adaptor recruitment27. Such effects are predicted to have
profound and more widespread effects on subsequent signalling
responses, so it seems unlikely that SCIMP exerts its effects by
promoting phosphorylation of this particular residue. Thus, TLR4
phosphorylation at Y674 may represent part of the tonic signal,
required for more widespread licensing of TLR4 signalling
responses in macrophages. In contrast, a previous study by
Ronni et al.47 identified surface-exposed residues within the TLR4
TIR domain that can contribute to selective transcriptional
regulation, including for the IL-12p40 promoter. Recruitment
of specific signalling complexes to phosphorylated TLR4 is
thus predicted to mediate the specific SCIMP-dependent
transcriptional programme, although this remains to be
formally demonstrated. Given the effect of SCIMP in driving a
transient MAPK signalling response (Fig. 3a,b and
Supplementary Fig. 2a), it is notable that SCIMP is also
associated with the Grb2 adaptor protein (Figs 1e,f and 2a) that
is linked to MAPK signalling responses18. This therefore
represents one candidate signalling component of the
SCIMP-dependent TLR4 response. Others include SLP
adaptors, to which SCIMP is also known to bind18.
Importantly, a functional connection between SCIMP-initiated
MAPK signalling and downstream biological responses on TLR
engagement is yet to be demonstrated. More in-depth studies of
SCIMP-dependent TLR signalling are thus required to
understand the precise molecular mechanisms by which this
adaptor imparts gene-specific control of TLR responses.
Nonetheless, our discovery that SCIMP functions downstream
of several TLRs (Supplementary Figs 3a–c and 4c,d) broadens its
likely biological significance to inflammatory responses, and puts
forth SCIMP-mediated tyrosine phosphorylation as a shared
mechanism across multiple TLRs.
Through protein–protein interaction studies, we demonstrate
that TLR4 and SCIMP uniquely and directly interact (Fig. 4b),
and, in cells, this interaction is agonist-induced (Figs 2a,5e and
6d,e). Mutational analysis delineated W95 and Y96 as critical
residues required for the interaction (Fig. 5), the latter in a
phosphorylation-dependent manner. Using recombinant
proteins, in which Y96 was not phosphorylated, we demonstrated
that SCIMP bound to TLR4 with moderately high affinity
(Fig. 4d). However, this interaction between the recombinant
proteins clearly cannot capture all of the factors involved in cells,
where their proximity within membrane sub-domains and
post-translational modifications will also be important. Indeed,
on the basis of binding studies with peptides (Fig. 5c,d), we
predict that the binding affinity between SCIMP and TLR4 would
be greatly enhanced on SCIMP phosphorylation at Y96, as occurs
upon LPS activation. Interestingly, the C-terminal T2 SCIMP
protein (amino acids 93–150) showed a reduced capacity to
pull-down TLR4 from activated macrophage cell extracts, by
comparison to a protein encompassing the entire intracellular
domain (T1, amino acids 29–150; Fig. 4c). This suggests that
other residues distal to the region around W95 and Y96 are likely
involved in binding to the TLR4 TIR domain. Hence, multiple
regions in the cytosolic domain of SCIMP must be involved in
supporting in its binding to TLR4.
Innate immune cells produce a wide range of inflammatory
cytokines. SCIMP appears to drive the TLR4-dependent produc-
tion of primarily two of these, namely IL-6 and IL-12p40. Why
only these cytokines are independently controlled is now an open
question. However, it is notable that both IL-6 and IL-12p40
control T helper (Th) cell differentiation programs. IL-6
promotes Th17 cell differentiation and limits T regulatory cell
development48, IL-12 directs Th1 cell differentiation, and
IL-12p40 homodimers can repress Th1 development49. As
SCIMP drives production of IL-6 and IL-12p40 (Fig. 3c,d), but
not IL-12p70 (Supplementary Fig. 2c), this may provide a
molecular switch favouring Th17 over Th1 differentiation
through the generation of IL-12p40 homodimers and IL-6. The
first published study on SCIMP identified a role in MHC class II
signalling18. Thus, an attractive model is that SCIMP may serve
dual adaptor roles in coordinating Th development programs;
first by promoting TLR-inducible expression of cytokines that
regulate Th development, and second by modulating MHC class
II signalling during antigen presentation18. In such a scenario,
SCIMP would be predicted to be a key player in shaping adaptive
immune pathways, particularly given that it controls the
production of Th polarizing cytokines downstream of multiple
TLRs (Supplementary Fig. 3a–c).
The identification of a TRAP that relays TLR responses now
brings this family of innate immune receptors in line with T and
B cell receptors, which are well known for partnering with
other TRAP family members to control signalling outputs in
lymphocytes. Through the identification of a very distinct
non-TIR adaptor pathway, our study highlights how the SCIMP
signalling complex mediates TLR4 tyrosine phosphorylation to
relay and customize downstream signalling. In so doing, we have
delineated proximal innate immune cell-specific signalling events
that initiate early signal bifurcation from TLR4, as part of a more
comprehensive signalling mechanism that is yet to be fully
elucidated (for example, via Grb2 and SLP adaptors), to drive
selective transcriptional responses and cytokine outputs. This
molecular mechanism involving immune-restricted SCIMP can
thus contribute to the exquisite specificity and potency of innate
immune cells in generating specific inflammatory cytokine
outputs for sculpting of appropriate inflammatory responses.
The accompanying predictions that SCIMP will be important as a
disease regulator are in keeping with emerging links between
SCIMP and inflammation-related diseases20,21.
Methods
Antibodies and reagents. The SCIMP antibody was produced by the Walter and
Eliza Hall Institute antibody facility. GST-SCIMP-T1 was expressed in Escherichia
coli (E. coli). After PreScission protease cleavage of the GST tag, the SCIMP
intracellular domain (amino acids 29–150) was further purified by gel filtration
using a Superdex S75 column (GE healthcare) and was used for immunizing
rabbits and antibody production. Primary antibodies recognizing His-tag (2366,
clone number 27E8), Grb2 (3972, lot 5), p56 Lyn (2796, clone number C13F9),
phospho-Src Family (Tyr416; 6943, clone number D49G4), phospho-p38 MAPK
(Thr180/Tyr182; 4511, clone number D3F9), IkBa (9242, lot 6), phospho-SAPK/
JNK (Thr183/Tyr185; 9251, lot 8) and phospho-ERK1/2 (4370, clone number
D13.14.4E) were purchased from Cell Signaling Technology (Beverly, MA, USA).
The GST antibody (71–7,500, clone number 1610744A) was purchased from
Invitrogen Australia. The anti-flotillin antibody (610820, clone number clone 18)
was purchased from BD BioSciences. The anti-actin antibody targeting the
N-terminal two thirds of the protein (MAB1501, clone number C4) was purchased
from Millipore Australia. The anti-TLR4 antibody targeting TLR4 amino acids
100–200 (ab22048, clone number 76B357.1), used for immunoprecipitation
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and western blotting, was from Abcam. For cell surface TLR4 staining by flow
cytometry, an APC-conjugated anti-mouse CD284 (TLR4) antibody (145405, clone
number SA15–21) from BioLegend was used (0.5 mg per million cells). The mouse
anti-glyceraldehyde-3-phosphate dehydrogenase antibody (2275-PC-1) was
purchased from Trevigen (Gaithersburg, MD, USA). The mouse anti-HA antibody
was purchased from Covance (MMS-101P, clone number 16B12), and the mouse
anti-V5 antibody (MCA1360, clone number SV5-PK1) was purchased from
Abacus ALS. The GFP antibody (A6455, lot 71BH) was purchased from Life
Technologies Australia (Scoresby, Victoria, Australia). All primary antibodies were
used at a 1:1,000 dilution for immunoblotting (with the exception of those against
phospho-p38 (1:500), IkBa (1:500) and phospho-ERK1/2 (1:650)), at a 1:100
dilution for immunofluorescence staining (with the exception of the antibody
against V5 (1:500)), at a 1:200 dilution for immunogold staining, and at a 1:50
dilution for immunoprecipitation, unless stated otherwise. Donkey anti-mouse
Alexa Fluor 594- (A-21203), donkey anti-rabbit Alexa Fluor 488- (A-21206) and
647- (A31573) conjugated secondary antibodies, Rhodamine Phalloidin (R415) and
Alexa Fluor 647 Phalloidin (A22287) were purchased from Molecular Probes
(Thermo-Fisher, CA, USA). 40,6-Diamidino-20-phenylindole dihydrochloride was
purchased from Sigma-Aldrich. Horseradish peroxidase-conjugated goat anti-
mouse and rabbit antibodies (81–6520) were obtained from Zymed (San Francisco,
CA, USA). All secondary antibodies were used at a 1:10,000 dilution, unless stated
otherwise. Sequencing grade, modified trypsin (V5111) was purchased from
Promega Australia. SU6656 (572635) was purchased from Merck Australia and was
used at a final concentration of 5 mM. Bacterial LPS, purified from Salmonella
enterica serotype Minnesota Re 595, was purchased from Sigma-Aldrich. The TLR
agonists Poly(I:C) (Integrated Sciences), Imiquimod (Integrated Sciences) and
Pam3CSK4 (Life Research) were used at 30 mg ml 1, 20mg ml 1 and 15 ng ml 1,
respectively. All other chemicals and reagents were from Sigma-Aldrich, unless
otherwise stated.
DNA constructs and protein expression. The mouse SCIMP full-length
construct was amplified by PCR from cDNA (with and without stop codon) and
cloned into the pEF6/V5-His TOPO TA and pEGFP-C1 expression vectors. Y96F
and W95A mutants of full-length SCIMP were generated by PCR site-directed
mutagenesis and were confirmed by sequencing. The wild type and mutant SCIMP
sequences were then subcloned into the pMIG retroviral vector. GST-SCIMP T1
(amino acid 29–150) and T2 (amino acid 93–150) were subcloned into pGEX6p-1
(GE Healthcare Life Sciences). SCIMP-T1 (Y58F, W95A, Y96F, S97A, S98A, V99A
and Y120F) were generated using the QuikChange site-directed mutagenesis kit
(Stratagene) and confirmed by DNA sequencing. Sanger sequencing was performed
through the Australian Genome Research Facility (AGRF, Brisbane, Australia).
Mouse TLR4-TIR (amino acid 670–835), codon-optimized for bacterial expression,
was purchased from Genscript USA. It was then subcloned in to the pET28a vector.
All GST fusion proteins were expressed in E. coli and purified using glutathione-
Sepharose beads (Amersham Biosciences), and all 6His fusion proteins were
expressed in E. coli and purified using Ni-NTA-super flow beads (QIAGEN),
according to the manufacturer’s instructions. The TLR4-HA construct was
kindly provided by Prof. Bostjan Kobe (School of Chemistry and Molecular
Biosciences, University of Queensland). MAL was subcloned into pEGFP-N1
from MAL-Cerulean, a gift from Nicholas J. Gay, University of Cambridge, UK.
Cell culture and transfection. A University of Queensland institutional animal
ethics committee approved all animal experimentation. Bone marrow cells were
collected from femurs and tibias of 6–8-week-old specific pathogen-free C57Bl/6
mice. Lyn / mice (on a C57Bl/6 background), used in these studies, have
previously been described50. In brief, BMM were obtained by in vitro
differentiation of mouse bone marrow cells in RPMI 1640 supplemented with
2 mM L-glutamine (GlutaMAX), 10% heat-inactivated foetal bovine serum,
50 U ml 1 penicillin and 50mg ml 1 streptomycin (Thermo-Fisher) with
recombinant CSF-1 (10,000 U ml 1, a gift from Chiron), as described
previously51,52. The muscle was removed from the femoral and tibial bones,
and bones were cleaned with 70% ethanol. The bone cavity was flushed with
complete media and a 23G needle. Pooled bone marrow cells were cultured on
bacteriological Sterilin plates (ThermoFisher, Newport, UK; B1–2 plates per
bone), and differentiated BMM were used on day 6 or 7. Differentiating BMM were
replenished with fresh CSF-1 and medium on day 5. Cell culture conditions for all
cell lines used in this study, including RAW264.7, NIH3T3, L929, EL4, MOPC and
WR19M cells, have previously been described53. Immortalized MyD88-deficient
BMM (generously provided by Dr Ashley Mansell, Hudson Institute of Medical
Research, Melbourne, Australia) were cultured in the same media as BMM, except
without the addition of CSF-1. RAW264.7 empty vector and SCIMP stable cell
lines (wild type and Y96F mutants) were generated by electroporation. 5 106 cells
were transfected with 10mg of plasmid DNA at 240 V, 1,000 mF and N O. 48 h
after transfection cells were selected using blasticidin (Thermo-Fisher). Transient
transfection of RAW264.7 macrophages was performed using lipfectamine 2000
(Thermo-Fisher), according to the manufacturer’s instructions.
Immunoblotting. For immunoblot analysis, cells were lysed in lysis buffer (20 mM
Tris, pH 7.4, 100 mM NaCl, 1% NP-40 (Sigma)) with addition of cOmplete
protease inhibitors (Roche Applied Science) and phosSTOP tablets (Roche
Applied Science). Lysates were transferred to a polyvinylidene difluoride
membrane (BioTrace, NZ, USA), blocked with 5% skim milk in phosphate-
buffered saline (PBS)/0.1% Tween-20 buffer (TBS-T) and incubated overnight at
4 C with primary antibodies. After washing, membranes were incubated with a
secondary antibody for 1 h, then developed with a chemiluminescence reagent
(ECL, Detection Reagents, Thermo Scientific), according to the manufacturer’s
instructions. Blots were quantified either by Chemiluminescence using the
ChemicDoc and Image Lab Software (Bio-Rad Laboratories, Hercules, CA, USA)
or by densitometry of X-ray film (FUJIFILM, Tokyo, Japan) using ImageJ
version 1.43 (National Institutes of Health, MD, USA). Uncropped images of all
immunoblots are presented in Supplementary Figs 7–9.
Cell surface TLR4 staining and flow cytometry. BMM were harvested in PBS
containing 5 mM EDTA and 1% foetal bovine serum and blocked for 20 min on ice
with 2.4G2 (anti-CD16/CD32 antibody; Thermo Fisher). Cells were then stained
for 20 min on ice with an anti-TLR4 antibody directly conjugated to APC, washed
twice in ice-cold PBS containing 5 mM EDTA and 1% foetal bovine serum,
resuspended in 100ml of the same wash solution, and then analysed by flow
cytometry using a FACS Canto II (BD) to assess cell surface TLR4 levels.
siRNA knockdown. Day 6 or 7 BMM were harvested and washed twice in media.
Cells were resuspended in complete media at a concentration of 5 106 cells/
350 ml, and 10 ml 1 M HEPES (tissue culture grade) per ml of cells was added. 350ml
of the cell suspension was transferred to 0.4 cm electroporation cuvettes and mixed
with siRNAs against SCIMP or HDAC1 (control gene) to a final concentration of
0.5 mM or tissue culture grade water (no siRNA control) in a final volume of 400 ml.
Cells were electroporated at 240 V, 1,000 mF and N O. After electroporation, cells
were washed twice, counted and then plated at the appropriate cell number. Cells
were treated with indicated stimuli at either 24 or 48 h post-transfection. Sequences
of siRNAs used are: mScimp #1: sense sequence: 50-AGACAACCCUCAGCUUGG
UACUCAU-30 ; antisense sequence: 50-AUGAGUACCAAGCUGAGGGUUG
UCU-30 ; mScimp #2: sense sequence: 50-CAACCACCGAAACCCAGCACUC
UAA-30 ; antisense sequence: 50-UUAGAGUGCUGGGUUUCGGUGGUUG-30 ;
control (mHdac1 #1): sense sequence: 50-GAACUACCCACUGCGAGACGGC
AUU-30 ; antisense sequence: 50-AAUGCCGUCUCGCAGUGGGUAGUUC-30 .
CRISPR/Cas9-mediated gene knockout. CRISPRs were designed to target the
second exon of SCIMP, 77 nucleotides downstream of the first ATG, using the
Zhang Lab (MIT) CRISPR design tool (http://crispr.mit.edu). S.p. Cas9 Nuclease
3NLS (Cat No. 1074181), Alt-R CRISPR crRNA targeting SCIMP (50-GCCACCT
GCAGACACAGTAC-30) and Alt-R CRISPR tracrRNA (Cat No. 1072532) were
purchased from Integrated DNA Technologies, Singapore. RAW264.7 cells were
transfected with Cas9, hybridized crRNA and tracrRNA, along with a vector
encoding neomycin resistance for transient selection. Transfections were
performed using CRISPRMAX transfection reagent from Thermo-Fisher (Cat
No. CMAX00003). After G418 selection for 3 days, colonies were expanded and
tested by western blot for SCIMP knockout. Matched control lines were generated
by omitting the SCIMP specific crRNA from the transfection procedure.
Gene overexpression by retroviral transduction. Retroviruses were generated
in the PlatE virus packaging cell line (ATCC). PlatE cells were maintained in
DMEM with 2 mM L-glutamine (GlutaMAX), 10% heat-inactivated foetal bovine
serum and 50 U ml 1 penicillin and 50mg ml 1 streptomycin. PlatE cells were
transfected with retroviral expression constructs encoding wild-type SCIMP or
specific SCIMP mutants (Y96F, W95A) using lipofectamine 2000 (Thermo Fisher).
Media was changed at 24 h post-transfection, after which cells were cultured at
32 C for 48 h. At 72 h post-transfection, supernatants containing viral particles
were collected and filtered through a Millex-HV PVDF syringe filter. Day 2 murine
bone marrow cells were subjected to spin infection at 1,000 g for 2 h at 32 C.
At 48 h post spin infection, media was replaced, and after another 48 h, cells were
harvested and used for experiments.
Quantification of mRNA expression. RNA was harvested from cells using the
Direct-zol RNA MiniPrep with TRI-reagent (Zymo Research, Irvine, CA, USA).
RNA concentrations were determined by nanodrop ND1000 (Thermo scientific).
one microgram of the resulting RNA was DNaseI-treated using amplification grade
DNaseI (Life technologies), and then converted to cDNA using oligo dT primers
and Superscript III (Life technologies). Levels of mRNA for specific genes were
quantified by SYBR green qPCR using the Applied Biosystems ViiA7 Real
Time PCR system (Life technologies); 15 s at 95 C and 1 min at 60 C for 45 cycles.
mRNA levels of individual genes, relative to hypoxanthine guanine phosphor-
ibosyltransferase (Hprt), were determined using the DCt method. All primers used
for quantitative PCR are listed in Supplementary Table 1.
Protein–protein interaction studies and mass spectrometry. GST-SCIMP
sepharose beads were incubated with cell lysates from control or 30 min
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LPS-activated RAW264.7 macrophages for 1 h at 4 C with agitation. MicroSpin
columns (#27- 3565-01; GE Healthcare) were used for all pull-downs. Beads were
washed with ice-cold wash buffer (20 mM Tris, 150 mM NaCl, 1% NP-40, pH 7.4).
Elution was achieved conventionally by boiling in 2 sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS–PAGE) sample buffer for 5 min.
Macrophage extracts were prepared by lysis in ice-cold lysis buffer (20 mM Tris,
pH 7.4, 150 mM NaCl, 1% NP-40 (Sigma), cOmplete protease inhibitors (Roche
Applied Science), and PhosSTOP tablets (Roche Applied Science). The lysates were
centrifuged at 75,600 g for 15 min at 4 C. Supernatants were pre-cleared by the
addition of GST-Sepharose beads for 1 h, pelleted at 50 g for 5 min at 4 C, after
which supernatants were collected. GST-tagged recombinant proteins were then
incubated with an equal amount of cell lysate at 4 C for 1 h. Beads were washed
extensively with ice-cold 20 mM Tris pH 7.4 containing 150 mM NaCl, 1 mM DTT,
1% NP-40 and 1 mM PMSF, eluted in 2 SDS–PAGE sample buffer, resolved on
10% SDS–PAGE gels, and stained with Coomassie blue G250. Samples were
analysed by either immunoblotting or liquid chromatography–mass spectrometry
(LC MS)/MS.
LC MS/MS analysis was performed on a Shimadzu Prominence Nano HPLC
(Japan) coupled to a Triple TOF 5600 mass spectrometer (ABSCIEX, Canada)
equipped with a nano electrospray ion source (IMB Mass Spectrometry Facility,
The University of Queensland). Sample preparation and analysis was performed as
previously described24. Extracts (6ml) were injected onto a 50 mm 300 mm C18
trap column (Agilent Technologies, Australia) at 30 ml min 1. The samples were
desalted on the trap column for 5 min using 0.1% formic acid (aq) at 30 ml min 1.
The trap column was then placed in-line with the analytical nano high-
performance liquid chromatography column and a 150 mm 75 mm 300SBC18
column (Agilent Technologies, Australia) for mass spectrometry analysis. Linear
gradients of 1–40% solvent B over 35 min at 300 nl min 1 flow rate, followed by a
steeper gradient from 40 to 80% solvent B in 5 min were used for peptide elution.
Solvent B was held at 80% for 5 min for washing the column and returned to 1%
solvent B for equilibration, before injection of the next sample. Solvent A consisted
of 0.1% formic acid (aq) and solvent B contained 90/10 acetonitrile/0.1% formic
acid (aq). The ion spray voltage was set to 2,400 V, declustering potential (DP)
100 V, curtain gas flow 25, nebuliser gas 1 (GS1) 12 and interface heater at 150 C.
The mass spectrometer acquired 500 ms full-scan time-of-flight mass spectrometry
(TOF-MS) data followed by 20 by 50 ms full-scan product ion data in an
information-dependent acquisition mode. Full-scan TOF-MS data were
acquired over the mass range 350–1,400 and for product ion ms/ms 80–1,400. Ions
observed in the TOF-MS scan exceeding a threshold of 100 counts and a charge
state of þ 2 to þ 5 were set to trigger the acquisition of product ion, ms/ms
spectra of the resultant 20 most intense ions. The data were acquired and
processed using Analyst TF 1.6.1 software (ABSCIEX, Canada). Proteins were
identified by database searching using ProteinPilot v4.5 (ABSCIEX, Canada)
against the UniProt_Sprot_20130205 database (B106,000 entries of all
species searched, FDR of 1%). Search parameters were defined as a thorough
search using trypsin digestion, iodoacetamide cysteine alkylation and all
entries in the database. The mass spectrometry score is defined as a
measurement of peptide confidence from the ProteinPilot. Scoring algorithm:
score¼  log(1-(PercentConfidence/100)). For example, a score of 2¼ 99%
confidence. %Cov (coverage) refers to the percentage of all identified peptide(s)
relative to total amino acid sequence, whereas %Cov (50%) and %Cov (95%) refer
to peptide coverage with 50 and 95% confidence, respectively. Proteins were
considered as an identified hit if there was at least one peptide identified with 99%
confidence.
Co-immunoprecipitation experiments were performed as described
previously23. Briefly, cells were lysed by passage through successively smaller
needles in lysis buffer (20 mM Tris pH 7.4, 140 mM NaCl, 1% NP-40, 1 mM PMSF,
1 mM DTT, Complete Protease inhibitors (Roche Applied Science) and
phospho-Stop tablets (Roche Applied Science)). The supernatant was then
collected after centrifugation at 14,000 g for 15 min and used as the input.
For immunoprecipitation, cell lysates were incubated with GFP Nanotrap or
appropriate antibodies and protein G agarose beads (Thermo Fisher Scientific) for
1 h at 4 C. Beads were then washed with excess lysis buffer and bound proteins
were solubilized in SDS–PAGE sample buffer. Proteins were separated by 10%
SDS–PAGE and analysed by immunoblotting.
Kinetic analyses of the TLR4-SCIMP interaction. The interaction of SCIMP
with TLR4 was monitored using a Fluoromax-4 spectrofluorometer (HORIBA
Scientific), and was performed as previously described54. Briefly, SCIMP-T1 was
labelled with BODIPY FL Iodoacetamide (ThermoFisher Scientific), according to
the manufacturer’s instructions. Labelled SCIMP was excited at 350 nm, and
detection was through a cutoff filter at 512 nm. Fluorescently labelled SCIMP-T1
was titrated with unlabelled TLR4-TIR for the kinetic analysis. The FAM-labelled
phosphorylated and unphosphorylated SCIMP Y96 peptides [90GQPSAW(p)
YSSVKKVRNKKV107, or 90GQPSAWYSSVKKVRNKKV107] were synthesized by
Genescipt USA. The excitation and emission wavelengths used were 498 mm
and 518 nm, respectively. Fluorescently labelled SCIMP Y96 was titrated with
unlabelled TLR4-TIR for the kinetic analysis. The data obtained were fitted using
the programme Grafit. All fluorescence measurements were performed at 25 C in
30 mM Tris, pH 7.4, 150 mM NaCl and 1 mM dithiothreitol.
Sucrose density gradient separation. Sucrose density gradient separation of
membrane extracts was performed as previously described55. Briefly, RAW264.7
cells were lysed in homogenization buffer (1% Triton X-100, 10 mM Tris, pH 7.5,
150 mM NaCl, 5 mM EDTA), and the lysate was centrifuged at 2,000 g for 2 min at
4 C to pellet unbroken cells and nuclei. Supernatants were loaded onto a 45 to 5%
discontinuous sucrose gradient and centrifuged at 200,000 g in a TLS-55 rotor at
4 C for 18 h. Each fraction was collected from the top of the gradient and subjected
to SDS–PAGE separation, and was then analysed by immunoblotting.
ELISA and Legendplex cytometric bead arrays. Enzyme-linked immunosorbent
assays were performed to quantify levels of IL-6, IL-12p40 and TNF secreted from
BMM. 96-well maxisorp plates (Thermo Scientific) were coated with 50 ml primary
antibody in 0.1 M sodium bicarbonate at pH 9.6 overnight at 4 C. Plates were then
washed with phosphate buffered saline (PBS)/0.05% Tween-20 (PBST), blocked
with 200 ml blocking buffer (10% FCS in PBS) for 2 h at 37 C and then incubated
with 100 ml standards or samples overnight at 4 C. Plates were again washed with
PBST, treated with 50 ml secondary antibody made up in blocking buffer for 1 h at
37 C, washed with PBST, 100ml extravidin-peroxidase (1:1,000) was added, then
samples were incubated for 20–30 min at 37 C. Peroxidase activity was measured
colorimetrically by adding 50 ml 3,305,50-Tetramethylbenzidine substrate (Sigma-
Aldrich) and the reaction was stopped by the addition of 50 ml of 2 M H2SO4. The
absorbance was read at 450 nm using a Powerwave XS plate reader and the sample
concentrations were calculated by extrapolation from a quadratic curve analysis of
the standards. LEGENDplex bead-based immune assays (BioLegend) were per-
formed to determine secreted levels of IFNb, IL-10 and IL-12p70 in culture
supernatants. Experiments were performed as per the manufacturer’s protocol, and
data were captured using a FACS Canto II flow cytometer (BD). Analysis of the
data were performed using the LEGENDplex software with the default settings.
Fluorescence imaging and electron microscopy. Cells fixed in 4% paraf-
ormaldehyde (PFA) and solubilized with 0.1% Triton X-100 for 5 min were
immunolabelled with the SCIMP antibody, followed by an Alexa488-conjugated
anti-rabbit IgG. Wide-field imaging of endogenous SCIMP was taken with a 12-Mp
differential contrast camera (DP71; Olympus) on an upright microscope (BX-51;
Olympus) fitted for a 60NA 1.35 oil objective using the associated DPController
software (version 2.1; Olympus). Confocal imaging of V5-tagged SCIMP in
transfected cells was performed using the Ziess LSM 710 confocal microscope fitted
with a LD C-Apochromat  63/1.15 W objective. For cryo-immuno-electron
microscopy and gold labelling, GFP-SCIMP-transfected RAW264.7 cells were fixed
in 4% paraformaldehyde, embedded in warm gelatin and infused with poly-
vinylpyrrolidone (PVP)/sucrose overnight and then frozen in liquid nitrogen.
Ultrathin cryosections were collected onto formvar-coated grids and immunola-
belled with a GFP antibody using standard protocols followed by different sized
Protein A-gold secondary antibodies (kindly provided by J. Slot, University of
Utrecht, Utrecht, the Netherlands). Sections were viewed on a JEOL 1011 electron
microscope (JEOL Australasia, Brookswater, Australia) at 80 kV, and images were
captured using the iTEM analysis programme (Soft Imaging System, Olympus,
Berlin, Germany).
Cytotoxicity assays. The effect of SU6656 on BMM viability was assessed using
the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). Cell culture
supernatants were collected at 8 h post-LPS treatment, centrifuged at 500 g for
5 min and lactate dehydrogenase (LDH) release was assessed. Total LDH was
assessed by lysing control cells with 0.1% Triton X-100. The percentage of
macrophage cell death was then calculated as [(LDHtreatment—background)/
(LDHTotal—background)] 100.
Statistics. If not stated otherwise, data are presented as arithmetic means±s.e.m.
For direct comparison of one experimental variable, a Student’s t-test was used. For
data sets containing multiple comparisons, a one-way analysis of variance
(ANOVA) was performed, with Dunett’s post-test. All data sets subjected to
statistical analysis were compiled from 3 or more independent experiments.
In all statistical analyses, a P valueo0.05 was considered as statistically significant.
Statistics were calculated using GraphPad Prism version 7.0 (GraphPad Software,
San Diego, CA, USA).
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its Supplementary Information Files,
or are available from the corresponding authors upon request.
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